Key Takeaways AUNA reported higher Q4 revenues and adjusted net income, with Peru driving growth and Colombia stable.AUNA's Mexico unit showed early turnaround signs with steady revenues and expanded provider access.AUNA boosted liquidity, with cash up 42% and free cash flow rising 35% after refinancing.Auna S.A. (AUNA) released its fourth-quarter 2025 earnings report on March 10. The Latin America-based healthcare platform’s revenue and adjusted net income increased on a year-over-year basis. While challen ...

Key Takeaways Auna S.A.'s net leverage stood at 3.6X, with a target to reduce it below 3X over the medium term.AUNA saw a 35% rise in free cash flow and a 42% increase in cash balance, boosting flexibility.Auna S.A. refinanced $825M debt, cutting interest costs and extending maturities to aid deleveraging.As of the 2025 fourth-quarter end, Auna S.A.’s (AUNA) net leverage held steady at 3.6X Net Debt-to-Adjusted EBITDA. The company is aiming to reduce its leverage below 3X over the medium term, supported by ...

Key Takeaways AUNA's Peru revenues rose 11% YoY, driven by high-complexity services and new medical investments.AUNA's adjusted EBITDA in Peru grew 14%, with margins improving to 22.4% in Q4 2025.AUNA's Oncosalud revenues increased 10%, aided by membership growth and lower oncology MLR at 48.5%.Auna S.A.’s (AUNA) Peru business underscores the strength and predictability of its integrated healthcare model operating at scale. The segment remained a bright spot in the fourth quarter of 2025, with revenues incr ...

Key Takeaways Auna's Mexico revenues fell 3% in Q4 local currency but stayed flat sequentially, signaling stabilization.AUNA's oncology revenues jumped 35% sequentially on Opcion Oncologia integration and a new Oncocenter launchAuna extended the ISSSTELEON plan with a double-digit price hike and insurer incentives for oncology care.Auna S.A. (AUNA) reported its fourth-quarter 2025 results this week. Soft market conditions in Mexico weighed on the number of surgeries and emergency visits, leading to a 3% dec ...

Auna (NYSE:AUNA) Q4 2025 Earnings call March 11, 2026 08:00 AM ET Company ParticipantsAna María Mora - Head of Investor RelationsArtur Alves - Equity Research AssociateGisele Remy - CFO and EVPJesús Zamora - Executive Chairman and PresidentConference Call ParticipantsGiovanni Vescovi - Equity Research AnalystOperatorGood morning, and welcome to Auna's fourth quarter 2025 earnings conference call. My name is Ellie, and I will be your operator for today's call. At this time, all participants are in listen-onl ...

Financial Data and Key Metrics Changes - Consolidated adjusted net income reached PEN 136 million in Q4 2025, compared to PEN 36 million in the same quarter last year, with full-year adjusted net income more than tripling to PEN 336 million [9][22] - Consolidated revenue grew 6% at FX neutral in Q4, while adjusted EBITDA declined 14% FX neutral, reflecting Mexico's underperformance and an unfavorable year-over-year comparison in Colombia [10][19] - For the full year, revenue grew 4%, while EBITDA declined 3% [10][21] - Free cash flow grew 35% to PEN 582 million, and year-end cash position increased 42% to PEN 335 million [27][29] Business Line Data and Key Metrics Changes - Mexico's revenues declined 3% in Q4, but showed stabilization with unchanged revenues from the previous quarter [11][12] - Peru's revenue increased 11% during Q4, driven by growth in high complexity services and a record low medical loss ratio [16] - Colombia's revenue increased 6% for the quarter, with a full-year revenue increase of 4%, mainly driven by higher ticket prices [18] Market Data and Key Metrics Changes - Capacity utilization in healthcare services decreased 2.3 percentage points to 64%, particularly in Colombia [10] - In Mexico, out-of-pocket revenues increased to 12% of total revenues in December, reflecting early recovery stages [11] - The oncology medical loss ratio in Peru improved to a record low of 48.5% [16] Company Strategy and Development Direction - The company aims to recover growth levels in Mexico and expand its reach into larger segments of privately insured families [6][31] - Auna is focusing on diversifying away from intervened payers in Colombia and prioritizing cash flows through risk-sharing arrangements [31] - The company plans to continue investing in strategic growth initiatives, particularly in Mexico and Peru, with expected adjusted EBITDA growth of 12% FX neutral in 2026 [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the business and the outlook for 2026, citing improvements in Mexico's operations and strong performance in Peru [40][41] - The main risks to guidance include the pace of volume recovery in Mexico and macroeconomic conditions in operating markets [40] - Management highlighted the importance of maintaining a higher mix of services and specialties to improve margins in Mexico [84] Other Important Information - The company successfully refinanced $825 million in debt, improving its maturity profile and lowering interest expenses [9][29] - The extension of the healthcare plan with ISSSTE León is expected to result in a double-digit price increase for 2026 [49] - The Torre Trecca project is expected to commence operations in the second semester of 2028, representing a significant opportunity for Auna [52] Q&A Session Summary Question: Can you break down guidance by region or business line? - Management indicated that Mexico is expected to drive most of the improvement, but they are not providing guidance by country at this time [35][43] Question: What are the risks to your 2026 guidance? - Management noted that external factors such as political headwinds and operational challenges in Mexico were previously concerns, but they are now confident in the stability of the business [40] Question: Can you provide updates on the Torre Trecca project? - Management confirmed that Torre Trecca will commence operations in the second semester of 2028 and is expected to represent about 25% of the business in Peru at maturity [52] Question: What is the expected CapEx for 2026 and beyond? - Management stated that CapEx for 2026 is expected to be approximately 4% of revenue, focusing on maintenance investments and technology [61] Question: How is the board prioritizing capital allocation? - Management discussed the potential for share buybacks but emphasized that growth opportunities in Mexico would take priority [78]

Financial Data and Key Metrics Changes - Consolidated adjusted net income reached PEN 136 million in Q4 2025, compared to PEN 36 million in the same quarter last year, with full-year adjusted net income more than tripling to PEN 336 million [9] - Consolidated revenue grew 6% year-over-year in Q4, while adjusted EBITDA declined 14% FX neutral, reflecting Mexico's underperformance and unfavorable comparisons in Colombia [10] - For the full year, revenue grew 4%, while EBITDA declined 3%, with capacity utilization in healthcare services decreasing 2.3 percentage points to 64% [10][12] Business Line Data and Key Metrics Changes - Mexico's operations stabilized, with oncology revenues growing 35% compared to the previous quarter, although overall revenues in Mexico declined 3% in Q4 [11][12] - Peru's revenue increased 11% in Q4, driven by high complexity services and a record low medical loss ratio of 48.5% [15] - Colombia's revenue grew 6% in Q4, with a full-year increase of 4%, supported by higher ticket prices despite lower volumes [17] Market Data and Key Metrics Changes - Mexico's healthcare market remains soft, affecting surgeries and emergency visits, while Peru continues to outperform with strong pricing and operational scale [6][7] - Colombia's results align with objectives to grow while improving cash flow, with a higher mix of risk-sharing contracts [8] Company Strategy and Development Direction - The company aims to recover growth levels in Mexico and expand its reach into privately insured families, with a focus on integrating new management and initiatives [6][12] - Auna plans to enhance its oncology services and expand its addressable market through projects like the Centro Ambulatorio Trecca in Peru [29] - The company is diversifying away from intermediary payers in Colombia and prioritizing cash flows through risk-sharing arrangements [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the stability of the business and the outlook for 2026, citing improvements in Mexico's operations and strong performance in Peru [30][40] - The company expects adjusted EBITDA to increase by 12% FX neutral in 2026, supported by disciplined cost management and strategic growth initiatives [32] Other Important Information - Auna's debt refinancing of $825 million improved its capital structure, reduced interest expenses, and extended maturity profiles [9][28] - Free cash flow grew 35% to PEN 582 million, with a year-end cash position increasing 42% to PEN 335 million, providing funds for strategic investments [26] Q&A Session Questions and Answers Question: Can you break down your guidance by region or business line? - Management indicated that Mexico's recovery is expected to drive improvements, but they are not providing specific guidance by country at this time [34][42] Question: What are the risks to your 2026 guidance? - Management highlighted external factors such as macroeconomic conditions and the pace of volume recovery in Mexico as potential risks, but expressed confidence in achieving guidance [39][40] Question: Can you provide details on the Torre Trecca project? - The Torre Trecca project is expected to commence operations in the second half of 2028, with significant revenue contributions anticipated from the EsSalud partnership [51][52] Question: What is the expected CapEx for 2026? - The expected CapEx for 2026 is approximately 4% of revenue, focusing on maintenance investments and technology upgrades [61] Question: How is the company planning to ramp up occupancy in Mexico? - Management plans to manage occupancy and margins through a higher mix of complex services, aiming for gradual recovery in 2026 [84]

Q4 & FY 2025 Earnings Call Presentation March │ 2026 1 Disclaimer This presentation has been prepared by Auna S.A. ("Auna" or the "Company") solely for use at this presentation. This presentation is confidential to the recipient. Accordingly, any attempt to copy, summarize or distribute this presentation or any portion hereof in any form to any other party without the Company's prior written consent is prohibited. This presentation contains forward-looking statements. Forward-looking statements convey our c ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders before the market opens [1] Group 1: Premarket Gainers - Domo, Inc. (DOMO) is up 39% at $6.13 [3] - Auna SA (AUNA) is up 17% at $5.67 [3] - TMD Energy Limited (TMDE) is up 16% at $2.39 [3] - Acurx Pharmaceuticals, Inc. (ACXP) is up 14% at $3.31 [3] - Atomera Incorporated (ATOM) is up 11% at $5.58 [3] - Oracle Corporation (ORCL) is up 9% at $163.42 [3] - UniFirst Corporation (UNF) is up 8% at $280.84 [3] - Adial Pharmaceuticals, Inc. (ADIL) is up 8% at $1.99 [3] - VCI Global Limited (VCIG) is up 7% at $3.22 [3] - XTI Aerospace, Inc. (XTIA) is up 5% at $3.19 [3] Group 2: Premarket Losers - Raytech Holding Limited (RAY) is down 22% at $3.40 [4] - MiNK Therapeutics, Inc. (INKT) is down 15% at $11.39 [4] - ESGL Holdings Limited (OIO) is down 15% at $3.26 [4] - Trailblazer Holdings, Inc. (TBMC) is down 14% at $10.13 [4] - Groupon, Inc. (GRPN) is down 12% at $10.16 [4] - AeroVironment, Inc. (AVAV) is down 10% at $198.24 [4] - Brand Engagement Network, Inc. (BNAI) is down 10% at $32.83 [4] - Polaryx Therapeutics, Inc. (PLYX) is down 7% at $5.50 [4] - TIC Solutions, Inc. (TIC) is down 6% at $8.00 [4] - ENDRA Life Sciences Inc. (NDRA) is down 5% at $3.32 [4]

Core Viewpoint - Auna S.A. reported strong quarterly earnings, significantly exceeding expectations, indicating positive momentum in its financial performance [1][2]. Financial Performance - Auna S.A. achieved earnings of $0.53 per share, surpassing the Zacks Consensus Estimate of $0.13 per share, and showing an increase from $0.12 per share a year ago, resulting in an earnings surprise of +324.00% [1]. - The company posted revenues of $337 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 1.92% and up from $282 million year-over-year [2]. Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.18 on revenues of $321.28 million, and for the current fiscal year, it is $0.87 on revenues of $1.34 billion [7]. - Auna S.A. has a favorable estimate revisions trend, leading to a Zacks Rank 2 (Buy), suggesting that the stock is expected to outperform the market in the near future [6]. Industry Context - The Medical Services industry, to which Auna S.A. belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable environment for stocks in this sector [8]. - The performance of Auna S.A. may also be influenced by the overall outlook for the industry, as empirical research shows a strong correlation between stock movements and earnings estimate revisions [5][8].